원발성 진행성 다발성 경화증(PPMS) 치료 시장 보고서(2026년)

Primary progressive multiple sclerosis (PPMS) treatment involves medical and therapeutic strategies designed to manage and slow the progression of PPMS, a form of multiple sclerosis marked by a steady decline in neurological function from symptom onset without clear relapses or periods of remission. These treatments aim to modify disease activity, relieve symptoms, preserve mobility, and enhance overall quality of life.

The main drug types used in treating primary progressive multiple sclerosis (PPMS) include monoclonal antibodies, immunosuppressants, corticosteroids, and other drug categories. Monoclonal antibodies (mAbs) are laboratory-developed proteins engineered to selectively bind to specific antigens on diseased cells for therapeutic or diagnostic use. These medications are administered through various routes, including oral, intravenous, and other methods, and are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and additional distribution channels.

Tariffs have affected the ppms treatment market by increasing the cost of imported active pharmaceutical ingredients (apis) and biologics used in monoclonal antibodies and immunosuppressants. Segments such as intravenous therapies and specialty drugs are particularly impacted, with regions like Europe and Asia-Pacific experiencing higher import duties. This has led to increased treatment costs and supply chain realignments. Positively, tariffs have encouraged local manufacturing, regional production investments, and the development of cost-efficient biosimilars.

The primary progressive multiple sclerosis (ppms) treatment market research report is one of a series of new reports from The Business Research Company that provides primary progressive multiple sclerosis (ppms) treatment market statistics, including primary progressive multiple sclerosis (ppms) treatment industry global market size, regional shares, competitors with a primary progressive multiple sclerosis (ppms) treatment market share, detailed primary progressive multiple sclerosis (ppms) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the primary progressive multiple sclerosis (ppms) treatment industry. This primary progressive multiple sclerosis (ppms) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The primary progressive multiple sclerosis (ppms) treatment market size has grown rapidly in recent years. It will grow from $1.16 billion in 2025 to $1.31 billion in 2026 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to limited treatment options for ppms, reliance on corticosteroids for symptom management, low awareness of ppms among patients, underdeveloped hospital pharmacy infrastructure, slow adoption of immunosuppressants.

The primary progressive multiple sclerosis (ppms) treatment market size is expected to see rapid growth in the next few years. It will grow to $2.18 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to introduction of targeted monoclonal antibodies, increasing r&d in neurodegenerative disorders, expansion of hospital and online pharmacy networks, rising regulatory approvals for novel therapeutics, growth in patient awareness and early diagnosis programs. Major trends in the forecast period include rising adoption of monoclonal antibodies for ppms, increased focus on symptom management and quality of life, growth in intravenous drug administration preference, expansion of hospital and specialty pharmacy channels, development of novel therapeutics and combination therapies.

The increasing demand for effective treatments is anticipated to drive the growth of the primary progressive multiple sclerosis (PPMS) treatment market in the coming years. Effective treatments are medical interventions that alleviate symptoms, improve patient outcomes, or manage disease progression. The rising demand for effective treatments is mainly driven by the growing prevalence of chronic and complex conditions that require long-term care and advanced therapeutic solutions to enhance quality of life. In PPMS, effective treatments help slow disease progression by reducing inflammation and preserving neurological function, thereby limiting disability accumulation, improving long-term outcomes, and enabling patients to maintain greater independence in daily activities. For instance, in January 2024, according to the American Society of Gene & Cell Therapy, a US-based organization dedicated to gene and cell therapy, the number of gene therapies in Phase III clinical trials reached 33 in 2023, reflecting a 10% increase compared to 2022 and marking the first quarterly rise since the third quarter of 2022. Therefore, the growing demand for effective treatments is driving the growth of the primary progressive multiple sclerosis (PPMS) treatment market.

Major companies operating in the primary progressive multiple sclerosis (PPMS) treatment market are emphasizing the development of innovative therapies, such as monoclonal antibody drugs, to improve multiple sclerosis management. Monoclonal antibody drugs help treat multiple sclerosis by selectively targeting immune cells or proteins responsible for inflammation and nerve damage, thereby reducing disease activity and slowing symptom progression. For example, in February 2024, Roche Pharma India, an India-based pharmaceutical company, introduced Ocrevus (ocrelizumab), a monoclonal antibody therapy, for the treatment of multiple sclerosis in India. Ocrevus is recognized as the first and only approved disease-modifying therapy for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) in the country. The drug targets CD20-positive B cells involved in the abnormal immune response associated with MS and is administered as a twice-yearly intravenous infusion lasting approximately two hours, offering patients a convenient and effective treatment option.

In March 2024, Viatris Inc., a US-based healthcare company focused on expanding access to medicines, partnered with Mapi Pharma Ltd. to support the development and commercialization of GA Depot 40 mg for the treatment of multiple sclerosis. Through this collaboration, Viatris assists in advancing the regulatory and commercial pathway for GA Depot, a long-acting injectable formulation designed to improve treatment adherence and address unmet needs in multiple sclerosis care. Mapi Pharma Ltd. is an Israel-based pharmaceutical company specializing in depot and sustained-release drug delivery technologies for central nervous system disorders, including multiple sclerosis.

Major companies operating in the primary progressive multiple sclerosis (ppms) treatment market are F. Hoffmann-La Roche Ltd., Biogen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics Inc., Apitope International N.V., Atara Biotherapeutics Inc., Kyverna Therapeutics Inc., Clene Inc., Mapi Pharma Ltd., Abata Therapeutics Inc., MediciNova Inc., MedDay Pharmaceuticals SAS, AB Science S.A., Immunic AG, BrainStorm Cell Therapeutics Inc., TG Therapeutics Inc., EMD Serono Inc. (Merck KGaA), Mitsubishi Tanabe Pharma Corporation, Sanofi Genzyme, Alexion Pharmaceuticals (AstraZeneca Rare Disease), Viela Bio (Horizon Therapeutics), Receptos (Celgene/Bristol-Myers Squibb), Forward Pharma A/S, InnoCare Pharma, NervGen Pharma Corp., Priovant Therapeutics, Tiziana Life Sciences, Reata Pharmaceuticals, Biohaven Pharmaceutical Holding Company, Anokion SA

North America was the largest region in the primary progressive multiple sclerosis (PPMS) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary progressive multiple sclerosis (ppms) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the primary progressive multiple sclerosis (ppms) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary progressive multiple sclerosis (PPMS) treatment market consists of sales of ocrelizumab (ocrevus), mitoxantrone, baclofen, modafinil and oxybutynin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses primary progressive multiple sclerosis (ppms) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for primary progressive multiple sclerosis (ppms) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The primary progressive multiple sclerosis (ppms) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Type: Monoclonal Antibodies; Immunosuppressants; Corticosteroids; Other Drug Types
• 2) By Route Of Administration: Oral; Intravenous; Other Route Of Administrations
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Monoclonal Antibodies: Ocrelizumab; Rituximab; Ofatumumab; Ublituximab
• 2) By Immunosuppressants: Methotrexate; Azathioprine; Mycophenolate Mofetil; Cyclophosphamide
• 3) By Corticosteroids: Methylprednisolone; Prednisone; Dexamethasone; Hydrocortisone
• 4) By Other Drug Types: Biotin; Ibudilast; Laquinimod; Idebenone
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Biogen Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd.; Acorda Therapeutics Inc.; Apitope International N.V.; Atara Biotherapeutics Inc.; Kyverna Therapeutics Inc.; Clene Inc.; Mapi Pharma Ltd.; Abata Therapeutics Inc.; MediciNova Inc.; MedDay Pharmaceuticals SAS; AB Science S.A.; Immunic AG; BrainStorm Cell Therapeutics Inc.; TG Therapeutics Inc.; EMD Serono Inc. (Merck KGaA); Mitsubishi Tanabe Pharma Corporation; Sanofi Genzyme; Alexion Pharmaceuticals (AstraZeneca Rare Disease); Viela Bio (Horizon Therapeutics); Receptos (Celgene/Bristol-Myers Squibb); Forward Pharma A/S; InnoCare Pharma; NervGen Pharma Corp.; Priovant Therapeutics; Tiziana Life Sciences; Reata Pharmaceuticals; Biohaven Pharmaceutical Holding Company; Anokion SA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Artificial Intelligence & Autonomous Intelligence
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Monoclonal Antibodies For Ppms
  • 4.2.2 Increased Focus On Symptom Management And Quality Of Life
  • 4.2.3 Growth In Intravenous Drug Administration Preference
  • 4.2.4 Expansion Of Hospital And Specialty Pharmacy Channels
  • 4.2.5 Development Of Novel Therapeutics And Combination Therapies

5. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Analysis Of End Use Industries

• 5.1 Neurologists And Healthcare Providers
• 5.2 Hospitals And Clinics
• 5.3 Specialty Pharmacies
• 5.4 Patients With Ppms
• 5.5 Research Institutions And Clinical Trial Centers

6. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Segmentation

• 9.1. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Monoclonal Antibodies, Immunosuppressants, Corticosteroids, Other Drug Types
• 9.2. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Intravenous, Other Route Of Administrations
• 9.3. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
• 9.4. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Ocrelizumab, Rituximab, Ofatumumab, Ublituximab
• 9.5. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Sub-Segmentation Of Immunosuppressants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Methotrexate, Azathioprine, Mycophenolate Mofetil, Cyclophosphamide
• 9.6. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Methylprednisolone, Prednisone, Dexamethasone, Hydrocortisone
• 9.7. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Biotin, Ibudilast, Laquinimod, Idebenone

10. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Regional And Country Analysis

• 10.1. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 11.1. Asia-Pacific Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 12.1. China Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 13.1. India Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 14.1. Japan Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 15.1. Australia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 16.1. Indonesia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 17.1. South Korea Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 18.1. Taiwan Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 19.1. South East Asia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 20.1. Western Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 21.1. UK Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 22.1. Germany Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 23.1. France Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 24.1. Italy Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 25.1. Spain Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 26.1. Eastern Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 27.1. Russia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 28.1. North America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 29.1. USA Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 30.1. Canada Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 31.1. South America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 32.1. Brazil Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 33.1. Middle East Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

• 34.1. Africa Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Primary Progressive Multiple Sclerosis (PPMS) Treatment Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Regulatory and Investment Landscape

36. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Competitive Landscape And Company Profiles

• 36.1. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Company Profiles
  • 36.3.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Acorda Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Other Major And Innovative Companies

• Apitope International N.V., Atara Biotherapeutics Inc., Kyverna Therapeutics Inc., Clene Inc., Mapi Pharma Ltd., Abata Therapeutics Inc., MediciNova Inc., MedDay Pharmaceuticals SAS, AB Science S.A., Immunic AG, BrainStorm Cell Therapeutics Inc., TG Therapeutics Inc., EMD Serono Inc. (Merck KGaA), Mitsubishi Tanabe Pharma Corporation, Sanofi Genzyme

38. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

40. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market High Potential Countries, Segments and Strategies

• 40.1 Primary Progressive Multiple Sclerosis (PPMS) Treatment Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Primary Progressive Multiple Sclerosis (PPMS) Treatment Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Primary Progressive Multiple Sclerosis (PPMS) Treatment Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer